These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 22445946

  • 1. Cognitive reactivity, dysfunctional attitudes, and depressive relapse and recurrence in cognitive therapy responders.
    Jarrett RB, Minhajuddin A, Borman PD, Dunlap L, Segal ZV, Kidner CL, Friedman ES, Thase ME.
    Behav Res Ther; 2012 May; 50(5):280-6. PubMed ID: 22445946
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up.
    Jarrett RB, Thase ME.
    Contemp Clin Trials; 2010 Jul; 31(4):355-77. PubMed ID: 20451668
    [Abstract] [Full Text] [Related]

  • 4. Longitudinal social-interpersonal functioning among higher-risk responders to acute-phase cognitive therapy for recurrent major depressive disorder.
    Vittengl JR, Clark LA, Thase ME, Jarrett RB.
    J Affect Disord; 2016 Jul 15; 199():148-56. PubMed ID: 27104803
    [Abstract] [Full Text] [Related]

  • 5. Dysfunctional attitudes or extreme response style as predictors of depressive relapse and recurrence after mobile cognitive therapy for recurrent depression.
    Brouwer ME, Williams AD, Forand NR, DeRubeis RJ, Bockting CLH.
    J Affect Disord; 2019 Jan 15; 243():48-54. PubMed ID: 30223139
    [Abstract] [Full Text] [Related]

  • 6. Stable remission and recovery after acute-phase cognitive therapy for recurrent major depressive disorder.
    Vittengl JR, Clark LA, Thase ME, Jarrett RB.
    J Consult Clin Psychol; 2014 Dec 15; 82(6):1049-59. PubMed ID: 25045908
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Initial Steps to inform selection of continuation cognitive therapy or fluoxetine for higher risk responders to cognitive therapy for recurrent major depressive disorder.
    Vittengl JR, Anna Clark L, Thase ME, Jarrett RB.
    Psychiatry Res; 2017 Jul 15; 253():174-181. PubMed ID: 28388454
    [Abstract] [Full Text] [Related]

  • 9. Cognitive reactivity to sad mood provocation and the prediction of depressive relapse.
    Segal ZV, Kennedy S, Gemar M, Hood K, Pedersen R, Buis T.
    Arch Gen Psychiatry; 2006 Jul 15; 63(7):749-55. PubMed ID: 16818864
    [Abstract] [Full Text] [Related]

  • 10. Moderators of continuation phase cognitive therapy's effects on relapse, recurrence, remission, and recovery from depression.
    Vittengl JR, Clark LA, Jarrett RB.
    Behav Res Ther; 2010 Jun 15; 48(6):449-58. PubMed ID: 20163785
    [Abstract] [Full Text] [Related]

  • 11. Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder.
    Vittengl JR, Clark LA, Thase ME, Jarrett RB.
    Psychotherapy (Chic); 2015 Jun 15; 52(2):268-77. PubMed ID: 25985046
    [Abstract] [Full Text] [Related]

  • 12. Do comorbid social and other anxiety disorders predict outcomes during and after cognitive therapy for depression?
    Vittengl JR, Clark LA, Smits JAJ, Thase ME, Jarrett RB.
    J Affect Disord; 2019 Jan 01; 242():150-158. PubMed ID: 30176494
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Quantifying and qualifying the preventive effects of acute-phase cognitive therapy: Pathways to personalizing care.
    Jarrett RB, Minhajuddin A, Vittengl JR, Clark LA, Thase ME.
    J Consult Clin Psychol; 2016 Apr 01; 84(4):365-76. PubMed ID: 26654211
    [Abstract] [Full Text] [Related]

  • 15. How much cognitive therapy, for which patients, will prevent depressive relapse?
    Jarrett RB, Vittengl JR, Clark LA.
    J Affect Disord; 2008 Dec 01; 111(2-3):185-92. PubMed ID: 18358541
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Defined symptom-change trajectories during acute-phase cognitive therapy for depression predict better longitudinal outcomes.
    Vittengl JR, Clark LA, Thase ME, Jarrett RB.
    Behav Res Ther; 2016 Dec 01; 87():48-57. PubMed ID: 27591917
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.